Showing information for HMDB0002117 ('oleamide', 'fatty acid amide C20:0')

Metabolite information
HMDB ID HMDB0002117
Synonyms
(9Z)-9-Octadecenamide
(9Z)-Octadec-9-enamide
(Z)-9-Octadecenamide
(Z)-Octadec-9-enoate amide
(Z)-Octadec-9-enoic acid amide
(cis)-9-Octadecenoate
(cis)-9-Octadecenoic acid
(cis)-9-Octadecenoic acid amide
14C-Labeled oleamide
9,10-Octadecenamide
9-Octadecenamide
9Z-Octadecenamide
Adogen 73
Aliphatic amide
Amide O
Armid O
Armoslip CP
Crodamide O
Crodamide or
Diamide O 200
Diamit O 200
ELD
Elaidoylamide
Kemamide O
Octadecene amide
Oleate amide
Oleic acid amide
Oleyl amide
Oleylamide
Oleylamide, (e)-isomer
Petrac slip-eze
Polydis TR 121
Slip-eze
Tocris-0878
Unislip 1759
cis-9,10-Octadecenoamide
trans-9,10-Octadecenoamide
Chemical formula C18H35NO
IUPAC name
(9Z)-octadec-9-enamide
CAS registry number 301-02-0
Monoisotopic molecular weight 281.271864747

Chemical taxonomy
Super class Lipids and lipid-like molecules
Class Fatty Acyls
Sub class Fatty amides

Biological properties
Pathways (Pathway Details in HMDB)

The paper(s) that report HMDB0002117 as a lung cancer biomarker


The studies that identify HMDB0002117 as a lung cancer-related metabolite

Reference Country Specimen Marker function Participants (Case) Participants (Control)
Cancer type Stage Number Gender (M,F) Age mean (range) (M/F) Smoking status Type Number Gender (M,F) Age mean (range) (M/F) Smoking status
Guo et al. 2012 China serum diagnosis adenocarcinoma, squamous cell carcinoma, SCLC I, II, III, IV 58 39, 19 52 ± 12 / 52 ± 12 – healthy 495 251, 244 61 ± 10 / 63 ± 12 –
Li et al. 2014 China serum diagnosis NSCLC, SCLC – 23 12, 11 63.0 ± 9.8 / 59.4 ± 5.8 – healthy 23 11, 12 51.0 ± 11.1 / 56.3 ± 14.3 –
Chen et al. 2015b China serum – lung cancer – 30 – 61.58 ± 10.67 – healthy 30 – 60.35 ± 12.48 –
Chen et al. 2015b China serum – lung cancer – 30 – 61.58 ± 10.67 – before vs. after treatment (operation) 30 – 61.58 ± 10.67 –
Reference Chromatography Ion source Positive/Negative mode Mass analyzer Identification level
Guo et al. 2012 DI ESI positive FT-ICR MS/MS
Li et al. 2014 LC – positive Q-TOF MS/MS
Chen et al. 2015b LC ESI positive Q-TOF –
Chen et al. 2015b LC ESI positive Q-TOF –
Reference Data processing software Database search
Guo et al. 2012 – HMDB, Lipid maps
Li et al. 2014 MarkerLynx METLIN, HMDB, KEGG
Chen et al. 2015b Mass Hunter Qualitative Analysis Software (Agilent Technologies) METLIN
Chen et al. 2015b Mass Hunter Qualitative Analysis Software (Agilent Technologies) METLIN
Reference Difference method Mean concentration (case) Mean concentration (control) Fold change (case/control) P-value FDR VIP
Guo et al. 2012 PLS-DA, – – – – – –
Li et al. 2014 PCA, PLS-DA, OSC-PLS-DA, student’s t-test – – – 0.05 – 1.70
Chen et al. 2015b PCA, PLS-DA, independent t test – – 1.47 1.00e-03 – 1.39
Chen et al. 2015b PCA, PLS-DA, independent t test – – 1.35 1.00e-03 – 1.38
Reference Classification method Cutoff value AUROC 95%CI Sensitivity (%) Specificity (%) Accuracy (%)
Guo et al. 2012 ROC curve – male oleamide + long chain acyl carnitine: 0.883, Oleamide + Long chain acyl carnitine + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.983, female oleamide + long chain acyl carnitine: 0.879, Oleamide + Long chain acyl carnitine + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 0.993 male oleamide + long chain acyl carnitine:87.2, Oleamide + Long chain acyl carnitine + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100, female oleamide + long chain acyl carnitine:78.9, Oleamide + Long chain acyl carnitine + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100 male oleamide + long chain acyl carnitine: 84.1, Oleamide + Long chain acyl carnitine + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 100, female oleamide + long chain acyl carnitine: 92.3, Oleamide + Long chain acyl carnitine + LPC(18:1) + LPC(20:4) + LPC(20:3) + LPC(22:6) + SM(16:0/1): 93.1 –
Li et al. 2014 ROC curve analysis – – – – –
Chen et al. 2015b – – – – – –
Chen et al. 2015b – – – – – –